The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 March 2026•

1 min read

Tango Therapeutics Hits Record High on Clinical Collaboration with Erasca

Key Facts

1Tango Therapeutics (TNGX) stock hit a record high following the announcement of a collaboration deal.

2The collaboration with Erasca aims to test a combination therapy for patients with MTAP-deleted RAS-mutant cancers.

Shares of Tango Therapeutics (TNGX) surged to a new record high following the announcement of a clinical collaboration agreement with Erasca. The strategic partnership aims to evaluate a combination therapy specifically designed for cancer patients with MTAP-deleted RAS mutations. Under the terms of the deal, the companies will test the combination of ERAS-0015 and vopimetostat in upcoming clinical trials. This collaboration leverages the complementary strengths of both companies' oncology pipelines to address high unmet medical needs. Market participants responded favorably to the news, as clinical partnerships in the biotech sector often mitigate development risks and shared costs. The record-breaking stock performance underscores investor optimism regarding the potential efficacy of this novel therapeutic approach.